JPM Healthcare Conference, ASCO, ASH, and BIO International each demand a different message, a different audience, and a different compliance path. Most biotech and pharma teams run all of them off the same deck. We build the strategy, the compliance-ready materials, and the field coordination that make each event actually work.
The Problem
Compliance review eats your event timeline
Booth messaging, slide decks, and even giveaways have to clear Legal, Regulatory, and Medical before they touch a conference floor. Most marketing teams start that review two weeks before ASCO or BIO International, which is too late, and off-label promotion rules mean a single loose claim can get materials pulled. By the time approval comes back, the deadline for booth submission or session registration has already passed.
MSLs and field marketing operate in separate worlds
Medical Science Liaisons report through Medical Affairs and run their own KOL relationships, while marketing runs the booth and the swag. At most conferences neither side knows what the other is doing, so the same key opinion leader gets a cold outreach email from marketing the same week an MSL is already scheduling a scientific discussion. The result is a fragmented experience for the people you most need to influence.
Investor meetings and scientific sessions get the same playbook
JPM Healthcare Conference is an investor and partnering event. ASCO and ASH are scientific and clinical events built around poster sessions and abstract presentations. Companies that run both off one messaging deck end up either too clinical for investors or too commercial for KOLs and clinicians, and neither audience walks away convinced.
You can't prove event ROI on an 18-month sales cycle
Biotech and pharma deal cycles run 12 to 24 months from first contact to signed agreement, which means last-touch attribution never credits a conference for the pipeline it actually built. Marketing shows up to the board with attendance numbers and lead counts, the CFO asks what it turned into, and nobody has an answer because nobody built the tracking to connect a JPM meeting to a deal that closed 18 months later.
How We Help
We start with an audit, not a plan. That means walking your full event calendar for the year (JPM Healthcare Conference, ASCO, ASH, BIO International, plus any therapeutic-area-specific conferences relevant to your pipeline) and mapping each one against its actual purpose: investor and partnering, scientific and clinical, or commercial and customer-facing. Most companies have never done this segmentation, which is why the same booth message shows up at every event regardless of who's actually in the room.
From there we build the strategy layer: a distinct playbook for investor-facing events versus scientific and clinical events, built around what each audience needs to hear and what compliance will actually clear. For JPM, that means a partnering-meeting strategy and an investor narrative. For ASCO and ASH, that means poster session strategy, abstract timing, and a booth message that stays inside promotional claim boundaries without going so generic it says nothing.
Compliance is not a bolt-on step at the end. We build booth messaging, session materials, and sales aids with Legal, Regulatory, and Medical review baked into the production timeline from day one, so materials are pre-cleared well ahead of submission deadlines instead of getting rushed through review the week before the show.
We also fix the coordination gap between Medical Affairs and field marketing. That means a shared KOL engagement calendar so an MSL's scientific outreach and marketing's event outreach to the same key opinion leader are sequenced, not duplicated, and a joint pre-conference plan for who's meeting whom and why.
On execution, we run the field marketing function directly during the event window: booth staffing coordination, session and symposium logistics, HCP engagement tracking that stays compliant with Sunshine Act transfer-of-value reporting, and post-event follow-up sequencing tied into your CRM so leads and KOL touchpoints don't sit in someone's inbox.
Measurement is built for your actual sales cycle, not a 30-day attribution window. We track pipeline influence, not last touch, so a JPM partnering meeting or an ASCO poster session conversation that turns into a deal 14 months later still gets credited to the event that started it.
What's different from a traditional agency or in-house hire: we're fractional and embedded, not a vendor you brief once a quarter. We sit inside your marketing, medical affairs, and regulatory workflows the way an operator would, not the way an outside firm hands off a deck and leaves.
What we deliver
- Annual event calendar and prioritization across JPM Healthcare Conference, ASCO, ASH, BIO International, and therapeutic-area conferences
- Separate playbooks for investor-facing events versus scientific and clinical events
- Compliance-ready booth messaging and session materials pre-cleared through Legal, Regulatory, and Medical
- Joint KOL engagement calendar coordinating Medical Affairs, MSLs, and field marketing
- Sunshine Act-compliant HCP engagement and transfer-of-value tracking process for event spend
- Pipeline-influence attribution model built for 12-24 month sales cycles
- Post-event CRM follow-up sequencing for leads, KOL touchpoints, and investor meetings
If your booth message at ASCO and your partnering deck at JPM are the same deck, you're not under-messaging one audience, you're under-messaging both.
Our Methodology
We run this as a 90-day sprint, not an open-ended retainer. Days 1-30 are the audit: your event calendar, your current compliance review workflow, and how (or whether) Medical Affairs and field marketing coordinate today. We come out of this phase with a clear map of which events are investor-facing, which are scientific and clinical, and where the compliance bottlenecks actually live.
Days 31-60 are build: separate playbooks per event type, booth and session materials moving through Legal, Regulatory, and Medical review on a timeline that actually clears before submission deadlines, and a joint outreach calendar between MSLs and marketing so KOL touchpoints are coordinated instead of duplicated.
Days 61-90 are the first live event under the new system, plus the attribution model built to track pipeline influence over the following 12-24 months rather than a 30-day lead count. Unlike a traditional agency engagement that ends when the deck is delivered, we stay embedded through execution and adjust the playbook based on what actually happened on the floor.
How We Work
The first 30 days are diagnostic: we pull your event calendar, sit in on a compliance review cycle, and talk to whoever currently owns MSL relationships and whoever owns the booth budget, because at most companies those are two different people who don't talk. By day 30 you get a segmented event strategy and a compliance workflow that's actually built to hit submission deadlines instead of missing them.
Days 30-60 are build and pre-clearance: messaging, booth materials, and session content move through Legal, Regulatory, and Medical review with enough runway to actually clear before JPM, ASCO, ASH, or BIO deadlines hit, and we stand up the shared KOL outreach calendar between Medical Affairs and marketing.
Days 60-90 cover your next live event, run with the new playbook, plus the attribution tracking that will show you what that event actually contributed to pipeline over the following year and a half, not what it looked like in a 30-day lead report.
The team is a fractional event marketing lead plus supporting specialists, embedded directly in your marketing, medical affairs, and regulatory workflows rather than briefed once a quarter from the outside. If your biotech or pharma company needs event marketing that survives compliance review and actually shows up in pipeline, we should talk.
- Faster compliance turnaround on booth and session materials
- Coordinated MSL and field marketing outreach to KOLs instead of duplicated contact
- Distinct, audience-appropriate messaging for investor-facing versus scientific and clinical events
- Sunshine Act-compliant tracking of HCP engagement and transfer-of-value spend
- Pipeline-influence reporting on event spend that matches your actual sales cycle length
If your biotech & pharma company needs event & field marketing leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How is event marketing different for biotech and pharma companies compared to other industries?
Every piece of public-facing content, from a booth banner to a giveaway, can trigger off-label promotion scrutiny and has to clear Legal, Regulatory, and Medical before it ships. On top of that, a single conference calendar can include an investor event like JPM Healthcare Conference and a scientific event like ASCO in the same month, and those two audiences need completely different messaging.
What compliance review do we need before attending JPM Healthcare Conference or ASCO?
It depends on your company's internal Medical, Legal, and Regulatory review process, but booth messaging, slide decks, and any promotional claims typically need sign-off before submission deadlines, which for events like ASCO can be months ahead of the actual conference. We build materials with that review cycle factored into the production timeline from the start, not as a last-minute step, so approval doesn't become the reason you miss a deadline.
Can you help coordinate MSLs and field marketing around a conference?
Yes. We build a joint KOL engagement calendar so Medical Affairs and marketing know who's reaching out to which key opinion leader and why, which stops the common problem of a KOL getting a marketing email the same week an MSL is scheduling a separate scientific conversation.
How do you measure ROI on conference spend when our sales cycle is 18 months?
We build a pipeline-influence model rather than relying on last-touch or 30-day lead attribution, which is what most marketing teams default to and what fails to credit events for deals that close over a year later. That means tracking which accounts and contacts touched at JPM, ASCO, ASH, or BIO actually show up in your pipeline months down the line, tied into your CRM so the connection is visible instead of anecdotal.
Do you handle HCP engagement and Sunshine Act reporting for events?
We build the process for tracking healthcare provider engagement and transfer-of-value data at events so your Sunshine Act reporting obligations are covered by design rather than reconstructed after the fact. We don't file the reports themselves, that stays with your compliance or legal team, but we make sure the data capture happens in real time at the event instead of getting pieced together weeks later from expense reports.
What is the difference between an investor-facing event strategy and a scientific or clinical event strategy?
An investor-facing event like JPM Healthcare Conference runs on partnering meetings and a narrative about pipeline value, milestones, and capital efficiency. A scientific or clinical event like ASCO or ASH runs on poster sessions, abstract presentations, and conversations with clinicians and researchers who want data, not a pitch.
